National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
R01AI103947
United States
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)
R01AI155784
United States
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)
GM007062
United States
Cancer Prevention and Research Institute of Texas (CPRIT)
RP220582
United States
Citation
Journal: J Med Chem / Year: 2025 Title: Optimization of Species-Selective Reversible Proteasome Inhibitors for the Treatment of Malaria. Authors: Suraksha Gahalawat / Sneha Ray / Xiaoyu Zhang / Xiaoyi Deng / Yan Han / Zhe Chen / Aloysus Lawong / David M Shackleford / Kasiram Katneni / Gong Chen / Peng Li / Alice Ng / Longjin Zhong / ...Authors: Suraksha Gahalawat / Sneha Ray / Xiaoyu Zhang / Xiaoyi Deng / Yan Han / Zhe Chen / Aloysus Lawong / David M Shackleford / Kasiram Katneni / Gong Chen / Peng Li / Alice Ng / Longjin Zhong / Meiyu Hu / Mitchell McInerney / Wen Wang / Jessica Saunders / Daniel Collins / Jaya Jayaseelan / Cassandra L Noack / Bikash C Maity / Nirupam De / Benoît Laleu / Simon F Campbell / Margaret A Phillips / Susan A Charman / Joseph M Ready / Abstract: Malaria remains a critical global health challenge, with increasing resistance to frontline therapies necessitating novel drug targets. The proteasome has emerged as a promising target for ...Malaria remains a critical global health challenge, with increasing resistance to frontline therapies necessitating novel drug targets. The proteasome has emerged as a promising target for antimalarial drug discovery. This study describes efforts to optimize a series of species-selective reversible inhibitors targeting the 20S proteasome. Starting from the carboxypiperidine scaffold identified through a high-throughput viability screen, we conducted iterative structure-activity relationship studies, leading to the development of highly potent and selective inhibitors with good oral bioavailability. Lead compounds demonstrated nanomolar potency against blood-stage parasites and selective inhibition of the parasite proteasome over the human counterpart. Cryo-EM structural studies confirmed binding at the β5 subunit, while in vivo pharmacokinetic studies identified promising candidates for further development. These findings support proteasome inhibition as a viable strategy for novel antimalarial drug development.
In the structure databanks used in Yorodumi, some data are registered as the other names, "COVID-19 virus" and "2019-nCoV". Here are the details of the virus and the list of structure data.
Jan 31, 2019. EMDB accession codes are about to change! (news from PDBe EMDB page)
EMDB accession codes are about to change! (news from PDBe EMDB page)
The allocation of 4 digits for EMDB accession codes will soon come to an end. Whilst these codes will remain in use, new EMDB accession codes will include an additional digit and will expand incrementally as the available range of codes is exhausted. The current 4-digit format prefixed with “EMD-” (i.e. EMD-XXXX) will advance to a 5-digit format (i.e. EMD-XXXXX), and so on. It is currently estimated that the 4-digit codes will be depleted around Spring 2019, at which point the 5-digit format will come into force.
The EM Navigator/Yorodumi systems omit the EMD- prefix.
Related info.:Q: What is EMD? / ID/Accession-code notation in Yorodumi/EM Navigator
Yorodumi is a browser for structure data from EMDB, PDB, SASBDB, etc.
This page is also the successor to EM Navigator detail page, and also detail information page/front-end page for Omokage search.
The word "yorodu" (or yorozu) is an old Japanese word meaning "ten thousand". "mi" (miru) is to see.
Related info.:EMDB / PDB / SASBDB / Comparison of 3 databanks / Yorodumi Search / Aug 31, 2016. New EM Navigator & Yorodumi / Yorodumi Papers / Jmol/JSmol / Function and homology information / Changes in new EM Navigator and Yorodumi